Evidence map›Paper›PMID 23071071›Full record

ReviewJournal of dental research2013

Parathyroid hormone applications in the craniofacial skeleton.

H L Chan, L K McCauley

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Journal of dental research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06061354 (Bone Microarchitecture and Implant Stabilization in Atrophic Jaws Reconstructed With Bone Grafts Treated With Teriparatide), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06061354 phase4unknown statusnot on this mapstarted 2023, after this paper: background citation

Bone Microarchitecture and Implant Stabilization in Atrophic Jaws Reconstructed With Bone Grafts Treated With Teriparatide

TypeinterventionalSponsorUniversidad de ValparaisoRan2023 to 2024Enrolled42ConditionsBone RegenerationArmsTeriparatide, Maxillary Sinus Augmentation, Dental Implant Installation, Bone graft
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Anabolic actions of parathyroid hormone in a hypophosphatasia mouse model.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. [Osteoprotegerin/receptor activator of nuclear factor-κB ligand expression in mandibular distraction osteogenesis regulated by parathyroid hormone].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2016
    Article
  17. PTH and Vitamin D.Comprehensive Physiology · 2016
    Review
  18. Tissue engineering for bone regeneration and osseointegration in the oral cavity.Dental materials : official publication of the Academy of Dental Materials · 2015
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

H L ChanDepartment of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA.
L K McCauley
University of Michigan–Ann Arbor · US

Funding

ANABOLIC MECHANISMS OF PTH ACTION IN BONER01DK053904 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MCCAULEY, LAURIE K. · 1998 to 2016
$4.6M
PTH and Calcium Synergy for Craniofacial RegenerationR01DE022327 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MCCAULEY, LAURIE K. · 2012 to 2022
$3.8M
Anabolic Mechanisms of PTH Action in BoneR56DK053904 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MCCAULEY, LAURIE K. · 2018 to 2018
$156k
NIDCR NIH HHS DE022327NIDCR NIH HHS R01 DE022327NIDDK NIH HHS DK53904NIDDK NIH HHS R01 DK053904NIDDK NIH HHS R56 DK053904
6 · The paper itself

Abstract

Parathyroid hormone (PTH) is known for its ability to 'build' bone, with research in this area centered on its use as an osteoporosis therapeutic. Recent interest has developed regarding its potential for regenerative applications such as fracture healing and osseous defects of the oral cavity. Many years of investigation using murine gene-targeted models substantiate a role for signaling at the PTH/PTH-related protein (PTHrP) receptor (PPR) in intramembranous bone formation in the craniofacial region as well as in tooth development. Pre-clinical studies clearly support a positive role of intermittent PTH administration in craniofacial bones and in fracture healing and implant integration. A few human clinical studies have shown favorable responses with teriparatide (the biologically active fragment of PTH) administration. Favorable outcomes have emerged with teriparatide administration in patients with osteonecrosis of the jaw (ONJ). New delivery strategies are in development to optimize targeted application of PTH and to help maximize local approaches. The promising host-modulating potential of PTH requires more information to further its effectiveness for craniofacial regeneration and osseous wound-healing, including a better delineation of cellular targets, temporal effects of PTH action, and improved approaches for local/targeted delivery of PTH.

Indexed as

AnimalsBone Density Conservation AgentsBone DiseasesBone RegenerationDisease Models, AnimalFacial BonesHumansOsteonecrosisParathyroid HormoneSkullTeriparatideBone Density Conservation AgentsParathyroid HormoneTeriparatide

Identifiers

PMID23071071
PMCPMC3521450
OpenAlexW2171313636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.